HuGE Literature Finder
Records
1
-
7
| First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangements. European journal of cancer (Oxford, England : 1990) 2022 Sep 173 238-249. Ma Yuxiang, Zhao Hongyun, Xue Jinhui, Liu Li, Yang Nong, Zhang Yang, Yang Haiyan, Hong Shaodong, Xiong Yi, Zhang Zhonghan, Zeng Liang, Pan Hui, Zhou Chunhua, Zhang Yongchang, Wang Xunqiang, Han Xi, Wan Xiaojing, Shao Yang, Liu Jingwen, Yang Yunpeng, Huang Yan, Zhao Yuanyuan, Fang Wenfeng, Li Su, Zhang |
| Phase 1b dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple negative breast, and ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Sep . Westin Shannon N, Labrie Marilyne, Litton Jennifer K, Blucher Aurora, Fang Yong, Vellano Christopher P, Marszalek Joseph R, Feng Ningping, Ma Xiaoyan, Creason Allison, Fellman Bryan, Yuan Ying, Lee Sanghoon, Kim TaeBeom, Liu Jinsong, Chelariu-Raicu Anca, Chen Tsun Hsuan, Kabil Nashwa, Soliman Pamela T, Frumovitz Michael, Schmeler Kathleen M, Jazaeri Amir, Lu Karen H, Murthy Rashmi, Meyer Larissa, Sun Charlotte, Sood Anil K, Coleman Robert L, Mills Gordon |
| Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma. Investigational new drugs 2021 Mar . Zauderer Marjorie G, Alley Evan W, Bendell Johanna, Capelletto Enrica, Bauer Todd M, Callies Sophie, Szpurka Anna M, Kang Suhyun, Willard Melinda D, Wacheck Volker, Varghese Anna |
| Safety and pharmacokinetics of veliparib extended-release in patients with advanced solid tumors: a phase I study. Cancer medicine 2018 May . Werner Theresa L, Sachdev Jasgit, Swisher Elizabeth M, Gutierrez Martin, Kittaneh Muaiad, Stein Mark N, Xiong Hao, Dunbar Martin, Sullivan Danielle, Komarnitsky Philip, McKee Mark, Tan Antoinette |
| Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential. The journal of prevention of Alzheimer's disease 2017 4 (3): 149-156. Abushakra S, Porsteinsson A, Scheltens P, Sadowsky C, Vellas B, Cummings J, Gauthier S, Hey J A, Power A, Wang P, Shen L, Tolar |
| A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecologic oncology 2015 Jun 137 (3): 386-91. Coleman Robert L, Sill Michael W, Bell-McGuinn Katherine, Aghajanian Carol, Gray Heidi J, Tewari Krishnansu S, Rubin Steven C, Rutherford Thomas J, Chan John K, Chen Alice, Swisher Elizabeth |
| Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. American journal of hematology 2015 Apr 90 (4): 276-81. Strati Paolo, Kantarjian Hagop, Ravandi Farhad, Nazha Aziz, Borthakur Gautam, Daver Naval, Kadia Tapan, Estrov Zeev, Garcia-Manero Guillermo, Konopleva Marina, Rajkhowa Trivikram, Durand Menda, Andreeff Michael, Levis Mark, Cortes Jor |
- Page last reviewed:Jul 25, 2022
- Page last updated:Nov 30, 2022
- Content source: